成功使用白介素-6抗体托珠单抗控制肺腺癌顽固性肿瘤热1例病例报道OA
A Case Report of Successful Control of Refractory Tumor Fever in Lung Adenocarcinoma with Interleukin-6 Antibody Tocilizumab
发热是肺癌较为常见的症状,但以合并感染多见.本文在国内首次报道了1例肺腺癌患者在使用一线治疗疾病进展再次活检后出现不明原因持续1个月以上的发热;经全面抽血、病原学检测及影像学检查均不支持感染性发热、结缔组织疾病发热、药物热等,继而诊断为肿瘤热;使用布洛芬后,患者发热仍难以控制,静脉给药1次托珠单抗12 h后即成功控制患者发热,并维持体温正常至随访日共45天(2025年8月21日至10月4日).本例报道为探讨肿瘤热发病机制及治疗策略提供了初步的实践经验.
Fever is a common symptom of lung cancer,but most are induced by infection.This is the first report of a patient with lung adenocarcinoma who developed a fever of unknown origin for more than 1 month after repeat biopsy on the progression of first-line treatment in China.Comprehensive blood tests,the well-known pathogens were fully examined,and imaging studies failed to support infectious fever,connective tissue disease-related fever,drug fever,or other etiologies,lead-ing to the diagnosis of tumor fever.While the fever remained refractory to Ibuprofen,it was successfully controlled 12 h after a single intravenous administration of Tocilizumab,with the patient maintaining a normal body temperature for 45 days,from August 21 to October 4,2025.This case report primarily provides the practice for exploring the tumor fever.
李颖;李春辉;李斌
410008 长沙,中南大学湘雅医院内科410008 长沙,中南大学湘雅医院感染科410008 长沙,中南大学湘雅医院肿瘤内科
肺肿瘤肿瘤热白介素-6托珠单抗
Lung neoplasmsParaneoplastic feverInterleukin-6Tocilizumab
《中国肺癌杂志》 2026 (1)
77-80,4
This paper was supported by the grant from University-level Project of Central South University(No.2021JGB145,to Bin LI). 本文受中南大学校级项目(No.2021JGB145)资助
评论